The Tumor Immunology (Tl) Program Area brings basic and translational scientists together into an environment that has spawned novel, investigator-initiated immunotherapy clinical trials for melanoma, brain cancers, lymphomas, lung cancer and renal cell carcinoma, among others. The main goals of the Program Area are: 1) to provide an optimal interactive environment to enhance the understanding of tumor immunology, and 2) to develop novel immune-based clinical therapies for patients with cancer. Established intra- and inter-programmatic research areas include: 1) T cell receptor engineering for adoptive cell transfer therapy;2) new platforms for immune monitoring of T cell responses to cancer;3) non-invasive in vivo imaging of tumor antigen-specific T cells;4) immunotherapy for brain cancers;5) the relationship between inflammation and cancer;and 6) the use of antibody fusion proteins, immune-modulating antibodies and chemokines for cancer therapy. The Tl Program Area also houses research efforts both on gene therapy approaches to cancer treatment and on viral oncogenesis, including studies of HIV/AIDS. The Tl Program Area uses nearly all of the JCCC-supported infrastructure and shared resources. The Flow Cytometry Shared Resource is a key facility required for most (if not all) research projects within the Program Area. The Small Animal Imaging Shared Resource has made possible the pursuit of successful projects in T cell imaging, projects that are now being brought from preclinical models to patients. The JCCC/Human Gene Medicine Program Good Manufacturing Practices (GMP) suite has provided the required physical infrastructure for investigators in the Tl Program Area to manufacture cell and gene therapy products in-house, meeting all of the local, state and federal regulatory requirements for human administration. The Tl Program Area is comprised of 37 members, including six

Public Health Relevance

The treatment of cancer by promoting an anti-tumor immune response offers great promise for the future. The Tumor Immunology Program Area brings together basic, translational, and clinical researchers from multiple disciplines to realize this promise. A broad range of therapeutic strategies for enhancing the antitumor immune response are being pursued, with important intra- and inter-programmatic collaborations to test and monitor the success of each strategy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Law, Ivy Ka Man; Jensen, Dane; Bunnett, Nigel W et al. (2016) Neurotensin-induced miR-133α expression regulates neurotensin receptor 1 recycling through its downstream target aftiphilin. Sci Rep 6:22195
Young, Courtney S; Hicks, Michael R; Ermolova, Natalia V et al. (2016) A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell 18:533-40
Palanichamy, Jayanth Kumar; Tran, Tiffany M; Howard, Jonathan M et al. (2016) RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. J Clin Invest 126:1495-511
Van Dyk, Kathleen; Ganz, Patricia A; Ercoli, Linda et al. (2016) Measuring cognitive complaints in breast cancer survivors: psychometric properties of the patient's assessment of own functioning inventory. Support Care Cancer 24:4939-4949
Bostean, Georgiana; Crespi, Catherine M; Vorapharuek, Patsornkarn et al. (2016) E-cigarette use among students and e-cigarette specialty retailer presence near schools. Health Place 42:129-136
Aguilera-Sandoval, Christian R; Yang, Otto O; Jojic, Nebojsa et al. (2016) Supranormal thymic output up to 2 decades after HIV-1 infection. AIDS 30:701-11
Bauer, Margaret R; Harris, Lauren N; Wiley, Joshua F et al. (2016) Dispositional and Situational Avoidance and Approach as Predictors of Physical Symptom Bother Following Breast Cancer Diagnosis. Ann Behav Med 50:370-84
Horvath, Steve; Gurven, Michael; Levine, Morgan E et al. (2016) An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. Genome Biol 17:171
Ganz, Patricia A; Petersen, Laura; Bower, Julienne E et al. (2016) Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study. J Clin Oncol 34:816-24
Dooley, Larissa N; Ganz, Patricia A; Cole, Steve W et al. (2016) Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. J Affect Disord 197:43-50

Showing the most recent 10 out of 568 publications